PHS
MRTX

PFM Health Sciences’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

PFM Health Sciences’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,000
Closed -$2.65M – 92
2021
Q3 		$2.65M Buy
+15,000
New +$2.41M 0.08% 80
2021
Q1 		– Sell
-44,300
Closed -$9.73M – 108
2020
Q4 		$9.73M Sell
44,300
-112,800
-72% -$24.4M 0.34% 69
2020
Q3 		$26.1M Buy
+157,100
New +$21.5M 1.21% 33

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

PFM Health Sciences's MRTX Position: Q2 2023 in Review

PFM Health Sciences sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 318,948 shares — an estimated $11.9M sold.

PFM Health Sciences first reported a position in MRTX in Q1 2019 and held it in 9 quarters. The position peaked at $53.2M in Q3 2021. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • PFM Health Sciences reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • PFM Health Sciences sold 318,948 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $11.9M.
  • PFM Health Sciences first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and held it in 9 quarters.
  • PFM Health Sciences's Mirati Therapeutics, Inc. Common Stock position peaked at $53.2M in Q3 2021.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on PFM Health Sciences's 13F filing for Q2 2023, filed 14 Aug 2023.